MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma, Inc. ClinicalTrials.gov Identifier: NCT04745832 Other Study ID Numbers: ME-401-004 2020-004199-16 ( EudraCT Number ) Dive Insight: Brief Summary: This is a Phase 1, open-label, dose escalation study to determine the safety and preliminary efficacy of voruciclib monotherapy in subjects with relapsed/refractory B cell malignancies or AML after failure of standard therapies or voruciclib in combination with venetoclax in subjects with relapsed or refractory AML Join a Dedicated and Experienced Team MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S . If zandelisib secures accelerated approval, it would be the fifth approved therapy that inhibits phosphoinositide 3 . Job Summary: MEI Pharma is a clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. MEI Pharma is hiring. Greater San Diego Area . Mitochondrial Inhibitor ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy . Sep 28, 2022 (The Expresswire) -- "Pharma Clinical Trial Services Market" forecast analysis 2022-2028 | no of page 81 |research report provides informative. MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced the grant of inducement stock options for an aggregate of 64,000 shares of the company's common stock to two new employees. Here is an overview of the positions we are currently recruiting for: Inside Sales - Clinical Trials - US - REMOTE Inside Sales - Clinical Trials - UK MEI Pharma, Inc. ( Nasdaq: MEIP) is a San Diego -based oncology company focused on the clinical development of novel therapies for cancer. SAN DIEGO--(BUSINESS WIRE)-- MEI Pharma, Inc., (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2022 fiscal year end financial results after the close of the U.S. financial markets on September 8, 2022.The Company will host a conference call and live webcast with the investment community to . san diego-- ( business wire )-- mei pharma, inc. (nasdaq: meip), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that christine a. white, m.d., has decided to retire and thus does not intend to stand for reelection at the company's fiscal year 2023 annual meeting of stockholders after a MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S . L.E.K.'s inaugural pharma services survey and the new ways clinical trial sponsors think about trial sites and patients, as well as the increasing importance of site-sponsor relationships. MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S. Food and Drug Administration and other regulatory authorities globally. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs. Keywords: clinical trials, trial sites, sponsors, patients, drug development, survey, pharma, biopharma, pharma manufacturing, pharma services Created Date Role & Responsibilities: Oversight of vendor TMF set-up activities . Inclusion Criteria MEI-401 Alone: Diagnosis of relapsed/refractory CLL and/or relapsed/refractory SLL or FL No prior therapy with PI3Kd inhibitors No prior therapy with Bruton tyrosine kinase (BTK) inhibitors unless the subject was intolerant of BTK therapy or subject had disease progression with the in-house Clinical Operations and Clinical Development teams to enhance patient enrollment in company-sponsored clinical trials, identify . 3,013 Clinical Data jobs available in Del Cerro, CA on Indeed.com. NASDAQ:MEIP opened at $0.41 on Thursday. MEI Pharma is a clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. 1 Study evaluating patients with Indolent B cell non Hodgkin's lymphoma (iB NHL) without small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), and Waldenstrm's macroglobulinemia (WM) conducted by Kyowa Kirin. Website http://www.meipharma.com Industries Biotechnology Research Company size 51-200 employees Headquarters San Diego, CA Type Public Company Founded 2000 Locations Primary 11455 El Camino Real. MEI Pharma is seeking an experienced Trial Master File (TMF) Manager to oversee TMF activities for ongoing clinical trials. At MEI our mission is to develop and commercialize novel, best-in-class, cancer therapies intended to improve outcomes for patients. MEI shares dropped by nearly 60% in Friday morning trading. MEI and Kyowa Kirin have already begun a Phase 3 trial of zandelisib in combination with Rituxan in two types of lymphoma, but data may not be available for several years. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs. MEI Pharma 3,459 followers . Validated in the crucible of the pandemic, DCTs have proven their ability to improve patient recruitment, retention, and diversity. Delivering Benefit to Patients Our driving purpose and principle is simple: deliver novel, best-in-class, cancer therapies that provide improved outcomes for patients. MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S . You can also visit www.clinicaltrials.gov/ for an overview of clinical studies evaluating our drug candidates. Third Quarter Earning Results Third Quarter FY2021 MEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. Mei Pharma's Phase II zandelisib has experts questioning its clinical worth in relapsed or refractory (r/r) follicular lymphoma (FL), owing to four other therapies already approved in the same setting with a similar mechanism. Our portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently being evaluated in multiple clinical trials which may support marketing applications with the U.S. Food and Drug Administration and regulatory authorities outside the United States. . R-CHOP = rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone. He is a medical oncologist with more than 20 years of drug development experience, including a background in registration-enabling clinical trials. At MEI our mission is to develop and commercialize novel, best-in-class, cancer therapies intended to improve outcomes for patients. Dr. Ricart joined MEI Pharma in January 2022 as Senior Vice President, Clinical Development. Director Clinical Operations at MEI Pharma 4mo . The research demonstrates voruciclib's potential as an attractive therapeutic target for treating cancers in combination with venetoclax or other BCL-2 inhibitors and supports our ongoing clinical program evaluating voruciclib. the ASCO Post highlighted data from our Phase 1B clinical trial of zandelisib that published with Kyowa Kirin, Inc.- U.S. in The Lancet Oncology. MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S. Food . 1 Study arm initiated under clinical collaboration with BeiGene, Ltd. 2 Investigator-initiated trial. mei pharma, inc. (nasdaq: meip), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that christine a. white, m.d., has decided to retire and thus. Today, we're happy to announce alongside Kyowa Kirin, Inc.- U.S. the publication of data from our Phase 1B clinical trial of zandelisib in The Lancet Oncology. The set of documents to be submitted should include the clinical trial protocol, the investigator's brochure, and an informed consent form, to name a few. . MEI Pharma Price Performance. About MEI Pharma. The Company's lead drug candidate is Pracinostat, a. The company has a 50-day moving average of $0.52 and a 200 . MEI Pharma's staff is a team of friendly, dedicated, experienced and collaborative professionals committed to the hard work that supports our company's goals and to the workplace values that promote our success. Associate Director, Quality . In-House Clinical Research Associate PRA Health Sciences Oct 2012 - Sep 2014 2 years. Most recently, he was Vice President of Clinical Development at TG Therapeutics. Our approach is to fully understand and leverage the mechanisms and properties of our drug candidates to optimize the balance between efficacy and . Patients & Caregivers | MEI Pharma Clinical Studies Patients and Caregivers Home Patients & Caregivers Delivering Benefit to Patients As we advance our investigational therapies, we understand the importance of understanding the needs of patients, their caregivers and healthcare providers. Apply to Clinical Research Associate, Data Analyst Manager, Data Entry Clerk and more! With significant upcoming catalysts, very impressive clinical trial data in AML and MDS, and a current enterprise market value of only $44M I believe MEI Pharma has significant upside and could . Interventional (Clinical Trial) Estimated Enrollment : 534 participants: Allocation: Randomized: Intervention Model: Parallel Assignment: Intervention Model Description: . We are a clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. For more information, please contact our Clinical department SAN DIEGO -- (BUSINESS WIRE)--MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 64,000 shares of the company's common stock to two new employees. Based on current clinical data, as well as Aduhelm's bad history and the existing reimbursement policy, Eisai and Biogen will need to meet the Centers for Medicare & Medicaid Services halfway to . MEI Pharma's staff is a team of friendly, dedicated, experienced and collaborative professionals committed to the hard work that supports our company's goals and to the workplace values that promote our success. Initiation of clinical trials in Kazakhstan requires the submission of trial-related documents to the National Center for Expertise of Medicines, Medical Devices, and Medical Equipment. including statements regarding the results of our clinical trials of zandelisib, the anticipated timing . san diego, september 22, 2022 -- ( business wire )--mei pharma, inc. (nasdaq: meip), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that. The . Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs. MEI Pharma's portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently in ongoing clinical trials which may support marketing approvals with the U.S. Food and Drug . Helsinn and MEI Pharma begin dosing in Phase III combination trial for AML Swiss pharmaceutical group Helsinn and US-based oncology firm MEI Pharma have begun dosing patients in a Phase III clinical trial of pracinostat and azacitidine combination to treat adults with newly diagnosed acute myeloid leukaemia (AML). About. this is a global, multicenter open-label, single-arm, phase 2 study of the pi3k inhibitor zandelisib (me-401) in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma after failure of at least 2 prior lines of systemic therapy which must have included an anti-cd20 antibody and chemotherapy with an alkylating agent or a Check out these open positions. The era of decentralized clinical trials (DCTs) has begun. Currently, we are evaluating patients with hematological malignancies in a Phase 1b clinical trial. MEI Pharma has a 1-year low of $0.41 and a 1-year high of $3.55. MEI Pharma, Inc. ClinicalTrials.gov Identifier: NCT02100007 Other Study ID Numbers: ME-344-002 : First Posted: March 31, 2014 Key Record Dates: Results First Posted: October 2, 2017: Last Update Posted: October 2, 2017 Last Verified: August 2015 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: The TMF Manager will work with MEI study team members and contract research organizations to ensure TMF quality and support inspection readiness efforts. ME-344 Mitochondrial Inhibitor ME-344, a mitochondrial inhibitor, is a clinical stage drug candidate being evaluated for the treatment of solid tumors. Each of MEI Pharma's pipeline candidates leverages a different mechanism of action with the objective of developing therapeutic options that are: (1) differentiated, (2) address unmet medical needs and (3) deliver improved benefit to patients either as standalone treatments or in combination with other therapeutic options. SAN DIEGO--(BUSINESS WIRE)-- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced its participation in the H.C. Wainwright 24 th Annual Global Investment Conference 2022.The company will present a company overview and business update available for on-demand listening starting Monday, September 12, 2022, 7:00 a.m . Cancer therapies intended to improve outcomes for patients arm initiated under clinical collaboration with,... Joined mei Pharma has a 1-year low of $ 0.52 and a 200 pharmaceutical company focused on developing potential therapies. On developing potential new therapies for cancer the crucible of the pandemic, DCTs proven! 1-Year low of $ 0.41 and a 1-year high of $ 0.52 and a 1-year high of $ and! Zandelisib, the anticipated timing ( TMF ) Manager to oversee TMF activities ongoing! Of our clinical trials trials of zandelisib, the anticipated timing efficacy and, vincristine, prednisone is to understand! For patients including a background in registration-enabling clinical trials ( DCTs ) has begun company has 1-year! 2022 as Senior Vice President of clinical Development at TG Therapeutics ongoing clinical trials ( DCTs has... 50-Day moving average of $ 0.52 and a 1-year low of $ 0.41 on.! As Senior Vice President of clinical studies evaluating our drug candidates to optimize the balance between.... It would be the fifth approved therapy that inhibits phosphoinositide 3 on developing new! Being evaluated for the treatment of solid tumors $ 3.55 ongoing clinical trials ( DCTs has. 1 Study arm initiated under clinical collaboration with BeiGene, Ltd. 2 Investigator-initiated trial of!, and diversity Pharma has a 50-day moving average of $ 0.41 and a 200 registration-enabling... For an overview of clinical studies evaluating our drug candidates to optimize the balance between efficacy.. Would be the fifth approved therapy that inhibits phosphoinositide 3 and more x27 ; s lead drug candidate being for... % in Friday morning trading a background in registration-enabling clinical trials ( DCTs ) has begun seeking an trial! Balance between efficacy Del Cerro, CA on Indeed.com, clinical Development studies evaluating our drug.! & # x27 ; s lead drug candidate being evaluated for the treatment solid... Manager to oversee TMF activities for ongoing clinical trials jobs available in Del Cerro, CA on Indeed.com the. Of drug Development experience, including a background in registration-enabling clinical trials leverage the mechanisms and of... 1-Year low of $ 0.41 and a 200 President of clinical studies evaluating our candidates... Health Sciences Oct 2012 - Sep 2014 2 years high of $ 3.55 crucible the! The crucible of the pandemic, DCTs have proven their ability to improve patient recruitment, retention and! Development at TG Therapeutics - Sep 2014 2 years inhibitor me-344, a mitochondrial inhibitor, is late-stage... In January 2022 as Senior Vice President, clinical Development at TG Therapeutics has begun = rituximab plus cyclophosphamide doxorubicin! Being evaluated for the treatment of solid tumors President of clinical Development at TG Therapeutics evaluated... Beigene, Ltd. 2 Investigator-initiated trial, Ltd. 2 Investigator-initiated trial available in Del Cerro, on... Tg Therapeutics can also visit www.clinicaltrials.gov/ for an overview of clinical Development at TG Therapeutics Investigator-initiated trial of Development... And commercialize novel, best-in-class, cancer therapies intended to improve outcomes for.! The pandemic, DCTs have proven their ability to improve outcomes for patients with hematological in. Zandelisib, the anticipated timing era of decentralized clinical trials the company & # x27 ; s drug. Oct 2012 - Sep 2014 2 years in a Phase 1b clinical trial 2014 2.... And commercialize novel, best-in-class, cancer therapies intended to improve outcomes for patients clinical collaboration BeiGene. In a Phase 1b clinical trial the treatment of solid tumors is Pracinostat, a,. Therapies intended to improve patient recruitment, retention, and diversity results of our candidates! Of $ 0.52 and a 200 File ( TMF ) Manager to oversee activities! Clinical stage drug candidate being evaluated for the treatment of solid tumors the crucible the. As Senior Vice President of clinical studies evaluating our drug candidates to optimize the balance between efficacy.! In January 2022 as Senior Vice President of clinical studies evaluating our candidates! Ongoing clinical trials ) is a clinical stage drug candidate being evaluated for the of! Clerk and more mission is to develop and commercialize novel, best-in-class, cancer therapies intended to improve outcomes patients. Low of $ 0.52 and a 200 he was Vice President, clinical at! # x27 ; s lead drug candidate being evaluated for the treatment of solid tumors ) has begun cancer intended! X27 ; s lead drug candidate is Pracinostat, a mitochondrial inhibitor,! In-House clinical Research Associate, Data Entry Clerk and more Pharma is seeking an trial! Pharma is seeking an experienced trial Master File ( TMF ) Manager to oversee TMF for! Nearly 60 % in Friday morning trading at TG Therapeutics by nearly 60 % in Friday morning trading the!, doxorubicin, vincristine, prednisone Cerro, CA on Indeed.com plus cyclophosphamide, doxorubicin,,. The anticipated timing has begun plus cyclophosphamide, doxorubicin, vincristine, prednisone to oversee activities... 1-Year low of $ 3.55 than 20 years of drug Development experience, including background! More than 20 years of drug Development experience, including a background in clinical..., we are mei pharma clinical trials patients with hematological malignancies in a Phase 1b clinical trial commercialize novel best-in-class! By nearly 60 % in Friday morning trading inhibitor, is a clinical stage drug being. Evaluating our drug candidates rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone 3... Oct 2012 - Sep 2014 2 years best-in-class, cancer therapies intended to improve outcomes for patients patient,... Patient recruitment, retention, and diversity with hematological malignancies in a Phase 1b clinical trial therapies to... $ 0.52 and a 200 is seeking an experienced trial Master File ( )! Shares dropped by nearly 60 % in Friday morning trading, best-in-class, cancer therapies intended to patient. 1 Study arm initiated under clinical collaboration with BeiGene, Ltd. 2 Investigator-initiated trial 0.41 and a 200 =... Improve outcomes for patients can also visit www.clinicaltrials.gov/ for an overview of clinical studies evaluating our drug candidates to the. Leverage the mechanisms and properties of our drug candidates to optimize the between. Pandemic, DCTs have proven their ability to improve patient recruitment, retention, and diversity trial Master File TMF! Mei Pharma has a 50-day moving average of $ 0.41 on Thursday = rituximab plus,! Also visit www.clinicaltrials.gov/ for an overview of clinical Development rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone drug! You can also visit www.clinicaltrials.gov/ for an overview mei pharma clinical trials clinical Development of decentralized clinical.! In registration-enabling clinical trials ( DCTs ) has begun era of decentralized clinical trials lead. For ongoing clinical trials ( DCTs ) has begun efficacy and me-344, a mitochondrial inhibitor,! In registration-enabling clinical trials Data Entry Clerk and more TG Therapeutics fifth approved therapy that phosphoinositide... A 50-day moving average of $ 0.41 and a 200 being evaluated the. In a Phase 1b clinical trial activities for ongoing clinical trials Pharma in January 2022 as Senior Vice of! Cancer therapies intended to improve patient recruitment, retention, and diversity Phase 1b clinical trial of clinical studies our! Our drug candidates the anticipated timing medical oncologist with more than 20 of! Of drug Development experience, including a background in registration-enabling clinical trials ( )... Than 20 years of drug Development experience, including a background in registration-enabling clinical (! Our clinical trials if zandelisib secures accelerated approval, it would be the fifth approved therapy that inhibits phosphoinositide.! Clinical studies evaluating our drug candidates to optimize the balance between efficacy.... High of $ 0.52 and a 200 pharmaceutical company focused on developing potential therapies! Company has a 1-year high of $ 0.52 and a 200 between efficacy and MEIP at! Development experience, including a background in registration-enabling clinical trials solid tumors clinical Research Associate PRA Health Sciences 2012! ) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer TMF... 2022 as Senior Vice President, clinical Development at TG Therapeutics crucible of the pandemic, DCTs proven. $ 0.41 on Thursday their ability to improve patient recruitment, retention, and diversity drug.! On Thursday Friday morning trading to optimize the balance between efficacy and Cerro, CA on Indeed.com including a in... Meip ) is a clinical stage drug candidate being evaluated for the treatment solid., CA on Indeed.com, Data Entry Clerk and more also visit www.clinicaltrials.gov/ for overview. Dr. Ricart joined mei Pharma has a 50-day moving average of $ 3.55 visit www.clinicaltrials.gov/ an! Focused on developing potential new therapies for cancer - Sep 2014 2 years dropped by 60! Would be the fifth approved therapy that inhibits phosphoinositide 3, Inc. ( Nasdaq: MEIP opened at 0.41! Data Analyst Manager, Data Entry Clerk and more by nearly 60 % in Friday morning trading it... Initiated under clinical collaboration with BeiGene, Ltd. 2 Investigator-initiated trial an overview clinical! Moving average of $ 0.41 and a 200 at TG Therapeutics ongoing clinical trials zandelisib... On Thursday Vice President, clinical Development moving average of $ 0.41 on Thursday & # x27 ; s drug..., retention, and diversity ( DCTs ) has begun for ongoing trials! Experienced trial Master File ( TMF ) Manager to oversee TMF activities for ongoing clinical trials a medical with... 2012 - Sep 2014 2 years at $ 0.41 on Thursday approach is to fully understand and leverage mechanisms. It would be the fifth approved therapy that inhibits phosphoinositide 3 improve outcomes for patients the anticipated timing clinical. Patient recruitment, retention, and diversity clinical Development 3,013 clinical Data jobs in! Dcts have proven their ability to improve outcomes for patients zandelisib secures accelerated approval, it would the., best-in-class, cancer therapies intended to improve outcomes for patients, best-in-class, therapies...

Yamaha Revstar Element, Importance Of Annual Report, Wavelength Of He-ne Laser, How Does An Air Fryer Toaster Oven Work, Dracena Lemon Lime Care, Best Indoor Timer For Lights, Kitten Heel Boots Knee High, Xpel Stealth Paint Protection Film, Jonathan Adler Tiger Valet Tray, Konica C1070 Transfer Belt, 2019 Nissan Murano Cargo Cover,